Table 3. Change from Baseline at Week 12 in Fasting Lipids (Modified Intent To Treat Analysis Set.

	Immediate Switch	Delayed Switch
Change From Baseline 12 Weeks post-switch	EFV/FTC/TDF (N = 79)	ABC/3TC+EFV(N = 74)	Delayed Switch to EFV/FTC/TDF a (N = 73)	p-value b	Diff in LSM (95% CI) c
Fasting Total Cholesterol (mmol/L)
N	79	73	68	<.001	−0.74 (−1.00, −0.47)
Median	−0.86	0.01	−0.73
p-value d	<.001	0.45	<.001
LDL Cholesterol (mmol/L)
N	79	73	68	<.001	−0.47 (−0.70, −0.25)
Median	−0.57	0.00	−0.61
p-value d	<.001	0.47	<.001
HDL Cholesterol (mmol/L)
N	78	73	68	<.001	−0.15 (−0.21, −0.08)
Median	−0.13	0.04	−0.14
p-value d	<.001	0.44	<.001
Triglycerides (mmol/L)
N	79	73	68	<.001	−0.43 (−0.75, −0.11)
Median	−0.26	0.02	−0.13
p-value d	<.001	1.00	0.063

^aDelayed Switch to EFV/FTC/TDF column includes subjects who were randomized to continue ABC/3TC+EFV at baseline and had at least 1 dose of EVF/FCT/TDF after switch at Week 12.

^bThe p-value for comparison between EFV/FTC/TDF and ABC/3TC +EFV at study Week 12 is from Wilcoxon rank sum test.

^cThe 95% confidence interval for the difference (EFV/FTC/TDF vs. ABC/3TC+EFV) is based on normal approximation.

^dThe p-value for within treatment group comparison is from Wilcoxon signed rank test.